UA125905U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis includes clinical examination, studies of low and high density lipoprotein cholesterol levels, arteriography, determination of eNOS T786C gene polymorphism in serum, endothelin content, folic acid, SOMP, SRP, homocyst. With homozygous carrier 786-SS, endothelin levels> 10 ng / ml, folic acid <6 ng / ml, COMP> 595 ng / ml, SRP> 6 mg / l, homocysteine> 20 μmol / l diagnose the development of atherosclerosis.

Description

The proposed method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of cholesterol levels of low and high density lipoproteins, arteriography of Ts|A.N. Okorokov

Diagnosis of diseases of internal organs. - M.: Med. lit., 2003. - Vol. 6. - P. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow early diagnosis of atherosclerosis.

The task is solved by the fact that, along with the study of low and high-density lipoprotein cholesterol levels, arteriography in the patient's blood serum determines the polymorphism of the nitric oxide synthase gene (6ЕМО5 77860), the content of endothelin, folic acid, cartilage oligomeric matrix protein (COMP), C-reactive protein (SRP), homocysteine. At a homozygous carrier of 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, COMP" 595 ng/ml, SRP 26 mg/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

Application of the method. During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. In the blood serum of the patient, the polymorphism of the eMmo5 1786C gene is determined, and the content of endothelin, folic acid, SOMR, SRP, and homocysteine is determined by the immunoenzymatic method. At a homozygous carrier of 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, COMP" 595 ng/ml, SRP 26 mg/l, homocysteine "20 μmol/l, the development of atherosclerosis is diagnosed.

A specific example of using the method.

Patient P., 54 years old, was hospitalized in the clinic with a diagnosis of rheumatoid arthritis. Examined

Low and high density lipoprotein cholesterol levels were studied. Arteriography was performed.

No signs of atherosclerosis were detected. Polymorphism of the eMOo5 7860 gene was determined in blood serum.

The content of endothelin, folic acid, SOMR, PSA,

From homocysteine. Homozygous carrier 786-SS was established. Levels of endothelin - 22 ng/ml, folic acid - 3.9 ng/ml, COMP - 634 ng/ml, PSA - 19 mg/l, homocysteine - 32 μmol/l. The development of atherosclerosis was diagnosed. Arteriographic confirmation of the diagnosis was obtained only after 13 months.

Thus, the proposed method of diagnosing the development of atherosclerosis allows to determine it in the early stages.

Claims (1)

USEFUL MODEL FORMULA The method of diagnosing the development of atherosclerosis, which includes a clinical examination, level research 40 low- and high-density lipoprotein cholesterol, arteriography, determination of the eMMO5 1786C gene polymorphism in the blood serum, the content of endothelin, folic acid, SMP, SRP, homocysteine, which is distinguished by the fact that with a homozygous carrier of 786-SS, endothelin levels are 210 ng/ml, folic acid "6 ng/ml, SMR "595 ng/ml, SRP 26 mg/l, homocysteine "20 μmol/l diagnose the development of atherosclerosis.